Mather Group LLC. Cuts Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Mather Group LLC. decreased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.2% in the fourth quarter, HoldingsChannel reports. The fund owned 3,887 shares of the pharmaceutical company’s stock after selling 128 shares during the quarter. Mather Group LLC.’s holdings in Vertex Pharmaceuticals were worth $1,565,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of VRTX. State Street Corp boosted its position in shares of Vertex Pharmaceuticals by 0.8% in the 3rd quarter. State Street Corp now owns 11,816,249 shares of the pharmaceutical company’s stock worth $5,495,501,000 after purchasing an additional 90,173 shares in the last quarter. Jennison Associates LLC boosted its holdings in Vertex Pharmaceuticals by 18.1% in the third quarter. Jennison Associates LLC now owns 5,550,386 shares of the pharmaceutical company’s stock worth $2,581,373,000 after acquiring an additional 851,054 shares in the last quarter. Wellington Management Group LLP boosted its holdings in Vertex Pharmaceuticals by 17.2% in the third quarter. Wellington Management Group LLP now owns 4,798,870 shares of the pharmaceutical company’s stock worth $2,231,858,000 after acquiring an additional 704,421 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Vertex Pharmaceuticals by 5.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 2,905,705 shares of the pharmaceutical company’s stock valued at $1,351,385,000 after acquiring an additional 159,693 shares in the last quarter. Finally, Janus Henderson Group PLC raised its position in shares of Vertex Pharmaceuticals by 4.1% in the 3rd quarter. Janus Henderson Group PLC now owns 2,516,831 shares of the pharmaceutical company’s stock valued at $1,170,506,000 after purchasing an additional 100,114 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Trading Up 2.5 %

Shares of Vertex Pharmaceuticals stock opened at $482.28 on Wednesday. The business has a 50 day simple moving average of $434.73 and a two-hundred day simple moving average of $462.62. Vertex Pharmaceuticals Incorporated has a 12 month low of $377.85 and a 12 month high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. Vertex Pharmaceuticals’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $3.67 earnings per share. As a group, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post -1.93 EPS for the current year.

Analyst Ratings Changes

Several research firms have weighed in on VRTX. Royal Bank of Canada boosted their target price on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 5th. Oppenheimer downgraded Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 19th. Wells Fargo & Company cut Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 price target for the company. in a research report on Thursday, January 30th. Barclays cut their price objective on Vertex Pharmaceuticals from $509.00 to $418.00 and set an “equal weight” rating on the stock in a report on Friday, December 20th. Finally, HC Wainwright lifted their target price on Vertex Pharmaceuticals from $535.00 to $550.00 and gave the stock a “buy” rating in a report on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $502.58.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.